278
T.A. Yousef et al. / Spectrochimica Acta Part A 83 (2011) 271–278
Table 7
[7] F. Kratz, V. Beyer, T. Roth, N. Tarasova, P. Collery, F. Lechenault, A. Cazabat, P.
Shumacher, C. Unger, U. Falkem, J. Pharm. Sci. 87 (1998) 338–346.
[8] S. Sivaramaiah, P.A. Reddy, J. Anal. Chem. 60 (2005) 828–832.
[9] S.H. Babu, K. Suvardhan, K.S. Kumar, K.M. Reddy, D. Rekha, P. Chiranjeeui, J.
Hazard. Mater. B 120 (2005) 213–218.
[10] S.A. Berger, J. Microchem. 47 (1993) 317–324.
[11] A.A. El-Emam, F.F. Belal, M.A. Moustafa, S.M. El-Ashry, D.T. El-Sherbing, S.H.
Hansen II, Farmaco 58 (2003) 1179–1186.
[12] M.S. Niasari, A. Amiri, Appl. Catal. 290 (2005) 46–53.
[13] P. Pelagalli, M. Cacelli, C. Pelizz, M. Costa, Inorg. Chim. Acta 342 (2003) 323–326.
[14] M.G. El-Meligy, S.E. El-Rafie, K.M. Abu-Zied, Desalination 173 (2005) 33–44.
[15] L.A. Cescon, A.R. Day, J. Org. Chem. 27 (1962) 581–586.
[16] I. Stylianakis, A. Kolocouris, N. Kolocouris, G. Fytas, G.B. Foscolos, E. Padalko, J.
Neyts, D. Clerq, E. Bioorg, Med. Chem. Lett. 13 (2003) 1699–1703.
[17] N.L. Allinger, J. Am. Chem. Soc. 99 (1977) 8127–8134.
[18] HyperChem version 8 Hypercube, Inc. (2002).
[19] O.A. El-Gammal, Spectrochim. Acta 75 (A) (2010) 533–542.
[20] J.I. Bullok, H.A. Tajmirriahi, J. Chem. Soc., Dalton Trans. 34 (1978).
[21] K. Nakamoto, Infrared Spectra of Inorganic and Coordination Compounds,
Wiley, New York, 1970.
Antimicrobial and antimycotic activities in terms of MIC (mg/ml) after 48 h.
Compound
S. aureus
E. coli
C. albicans
H2OS
6
5
2.6
3
5
4.8
3.6
2.1
5.8
6.7
2.1
–
–
–
2
–
–
–
–
1.8
–
7
7
[Cr(OS)NO3(H2O)]
[Mn(HOS)2(H2O)2]
[Fe(HOS)Cl2(H2O)]
[Co(HOS)2](H2O)2
[Co(HOS)(OAc)].2(H2O)
[Ni(HOS)Cl(H2O)3]
[Ni(HOS)(OAc)(H2O)2]
[Cu(HOS)(OAc)](H2O)
[Cu(HOS)Cl(H2O)]
Ampicilin
2.7
3.5
4
3.7
3
2.7
7.9
8
–
–
–
2.4
Nystatin
of the metal chelates can be explained on the basis of Overtone’s
concept and chelation theory [56]. According to Overtone’s con-
cept of cell permeability the lipid membrane that surrounds the cell
favours the passage of only lipid soluble materials due to which lip
solubility is an important factor that controls antimicrobial activ-
ity. On chelation, the polarity of the metal ion is reduced to a
greater extent due to the overlap of the ligand orbital and par-
tial sharing of the positive charge of the metal ion with donor
the whole chelate ring and enhances the lipophilicity of the com-
plex. This increased lipophilicity enhances the penetration of the
complexes into lipid membranes and blocking of metal binding
sites on the enzymes of the microorganism. It was observed from
Table 7, complexes [Cr(OS)NO3(H2O)], [Cu(HOS)(OAc)](H2O) and
[Cu(HOS)Cl(H2O)] were void of any antimicrobial activity.
[22] Y. Ihara, Y. Fukuda, K. Sone, Bull. Chem. Soc. Jpn. 59 (1986) 1825–1827.
[23] Y. Fukuda, C. Fujita, H. Miyamae, H. Nakagawa, K. Sone, Bull. Soc. Jpn. 62 (1989)
745–752.
[24] Y. Fukuda, R. Morishita, K. Sone, Bull. Chem. Soc. Jpn. 49 (1976) 1017–1022.
[25] S. Olavi, B.G. Harry, Inorg. Chem. 13 (1974) 1185–1191.
[26] C. Preti, G. Tosi, Aust. J. Chem. 29 (1976) 543–549.
[27] M. Palaniandavar, C. Natarajan, Aust. J. Chem. 33 (1980) 737–745.
[28] M.M. Mostafa, M.A. Khattab, K.M. Ibrahim, Polyhedron 2 (1983) 583–585.
[29] J.A. Bertrand, P.G. Eller, Inorg. Chem. 13 (1974) 927–934.
[30] A. Syamal, K.S. Kale, Indian J. Chem. A16 (1978) 46.
[31] L. Dubiki, R.L. Martin, Inorg. Chem. 5 (1966) 2203–2209.
[32] A.K. Gregson, R.L. Martin, S. Mitra, Proc. Roy. Soc. A320 (1971) 471–473.
[33] P. Manikandan, R. Muthukumaran, K.R.J. Thomas, B. Varghese, G.V.R. Chan-
dramouli, P.T. Manoharan, Inorg. Chem. 40 (2001) 2378–2389.
[34] G. Speie, J. Csihony, A.M. Whalen, C.G. Piepont, Inorg. Chem. 35 (1996)
3519–3524.
[35] B.J. Hathaway, D.E. Billing, Coord. Chem. Rev. 5 (1970) 143–207.
[36] V.T. Kasumo, Spectrochim. Acta A 57 (2001) 1649–1662.
[37] J.A. Wellman, F.B. Hulsbergen, J. Inorg. Nucl. Chem. 40 (1978) 143–147.
[38] R.K. Ray, G.R. Kauffman, Inorg. Chem. Acta 173 (1990) 207–214.
[39] K. Jayasubramanian, S.A. Samath, S. Thambidurai, R. Murugesan, S.K. Rama-
lingam, Transition Met. Chem. 20 (1995) 76–82.
4. Conclusion
[40] V.S.X. Anthonisamy, R. Murugesan, Chem. Phys. Lett. 287 (1998) 353–358.
[41] V.S.X. Anthonisamy, R. Anantharam, R. Murugesan, Spectrochim. Acta A 55
(1999) 135–142.
[42] N. Raman, Y.P. Raja, A. Kulandaisamy, Proc. Indian Acad. Sci. (Chem. Sci.) 113
(3) (2001) 183–189.
[43] R.P. John, Spectrochim. Acta A 59 (2003) 1349–1358.
[44] G.A.A. Al-Hazmi, M.S. El-Shahawi, E.M. Gabr, A.A. El-Asmy, J. Coord. Chem. 58
(8) (2005) 713–733.
[45] N.M. El-Metwally, E.M. Gabr, A.A. Abou-Hussen, A.A. El Asmy, Transition Met.
Chem. 31 (2006) 71–78.
A series of complexes, structures (2–4), were prepared from
the novel ligand (E)-2-(2-(2-hydroxybenzylidene)hydrazinyl)-
2-oxo-N-phenylacetamide (H2OS). Geometry optimization and
conformational analysis have been performed and the perfect
agreement with spectral studies allow for suggesting the exact
structure of all studies complexes. Most complexes have antibac-
terial activity against E. coli, S. aureus in addition antifungal against
C. albicans.
[46] S. Sagdinc, B. Koksoy, F. Kandemirli, S.H. Bayari, J. Mol. Struct. 917 (2009)
63–70.
[47] H.M. Irving, H.S. Rossotti, J. Chem. Soc. (1954) 1954–2904.
[48] A. Albert, E.P. Serjeant, The Determination of Ionization Constants, Chapman
and Hall Ltd, London, 1971.
Appendix A. Supplementary data
[49] H.M. Irving, R.J.P. Williams, J. Chem. Soc. (1953) 3192–3210.
[50] G.R. Choppin, J.L. Brock, Inorg. Chim. Scand. 9 (1985) 1166–1173.
[51] A.M. Hammam, S.A. Ibrahim, J. Electrochem. Soc. India 29–4 (1980)
273–281.
Supplementary data associated with this article can be found, in
[52] L.G. Van Uitert, W.C. Fernelius, B.E. Douglas, J. Am. Chem. Soc. 75 (1953)
2736–2738.
References
[53] A.A. El-Bindary, I.S. Shehatta, E.M. Mabrouk, Monatsh. Chem. 125 (1994)
373–384.
[54] P.R. Murray, E.J. Baron, M.A. Pfaller, F.C. Tenover, R.H. Yolken, in: G.L. Wood,
J.A. Washington (Eds.), Manual of Clinical Microbiology, Am. Soc. Microbiol.,
Washington, DC, 1995.
[55] R.N. Jones, A.L. Barry, T.L. Gavan, I.I.J.A. Washington, in: E.H. Lennette, A. Ballows,
W.J. Hausler Jr, H.J. Shadomy (Eds.), Manual of Clinical Microbiology, fourth edn,
Am. Soc. Microbiol. (1972), Washington DC, 1985.
[1] N. Terzioglu, A. Gürosy, Eur. J. Med. Chem. 38 (2003) 781–786.
[2] M.T. Cocco, C. Congiv, V. Lilliu, V. Onnis, Bioorg. Med. Chem. 14 (2006) 366–372.
[3] J. Easmon, G. Pverstinger, G. Heinish, J. Hofmann, Int. J. Cancer 94 (2001) 89–96.
[4] P. Vicini, F. Zani, P. Cozzini, I. Doytchinova, Eur. J. Med. Chem. 37 (2002)
553–564.
[5] J. Patole, U. Sandbhor, S. Padhe, D.N. Deobagkar, C.E. Anson, A. Powell, Bioorg.
Med. Chem. Lett. 13 (2003) 51–55.
[6] A. Walcourt, M. Loyevsky, D.B. Lovejoy, V.R. Gordeuk, D.R. Richardson, Int. J.
Biochem. Cell Biol. 36 (2004) 401–407.
[56] N. Raman, V. Muthuraj, S. Ravichandran, A. Kulandaisamy, Proc. Indian Acad.
Sci. 115 (2003) 161–167.